On December 13, 2024, the Food and Drug Administration sanctioned cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) inhibiting antibody, for adults with...
On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for use in adults with specific conditions.Patients with advanced, unr...
On November 20, 2024, the Food and Drug Administration granted accelerated approval for zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-targeted antibody, for previously tr...
On November 15, 2024, the Food and Drug Administration sanctioned revumenib (Revuforj, Syndax Pharmaceuticals, Inc.), a menin inhibitor, for relapsed or refractory acute leukemia characterized by a ...
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for people with...
On October 29, 2024, the Food and Drug Administration approved asciminib (Scemblix, Novartis AG) for adults who have just been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemi...
On October 18, 2024, the Food and Drug Administration sanctioned zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.), a claudin 18.2 (CLDN18.2)-targeted cytolytic antibody, in conjunction with fluor...
On October 10, 2024, the Food and Drug Administration authorized inavolisib (Itovebi, Genentech, Inc.) in conjunction with palbociclib and fulvestrant for adults diagnosed with endocrine-resistant, ...
On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...